Payment overview · 2025
General Payments
$1,364.17
67 reported records · 16 companies
Healthcare provider profile · identity verified
Robert L Thomas, MD
Allopathic & Osteopathic Physicians|Internal Medicine · WALTERBORO, SC · NPI 1750351508
Verified facts
What the public records show
CMS Open Payments records show Robert L Thomas, MD received $1,364.17 in general payments during 2025 across 67 reported records.
Grifols USA, LLC accounted for 13.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 20 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Airsupra, Sunosi, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AIRSUPRA as an associated drug or biological on 165148 records involving 56069 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Airsupra by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 85 claims for Symbicort by this doctor in 2024.
Axsome Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Sunosi as an associated drug or biological on 19758 records involving 6305 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Sunosi by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Jardiance by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OFEV as an associated drug or biological on 14236 records involving 6873 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Ofev by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 609 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $190.25 | 13.9% | 7 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $181.07 | 13.3% | 9 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $147.96 | 10.8% | 12 | 2025 |
| Avadel CNS Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $139.56 | 10.2% | 7 | 2025 |
| Insmed, Inc. | Unresolved — no canonical attribution shown | $113.59 | 8.3% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $99.28 | 7.3% | 5 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $85.45 | 6.3% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $80.62 | 5.9% | 5 | 2025 |
| Averitas Pharma Inc. | Unresolved — no canonical attribution shown | $68.82 | 5.0% | 1 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $68.75 | 5.0% | 4 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $52.47 | 3.9% | 2 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $36.13 | 2.6% | 2 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $34.20 | 2.5% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $33.00 | 2.4% | 1 | 2025 |
| Mallinckrodt Hospital Products Inc. | Unresolved — no canonical attribution shown | $17.02 | 1.2% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.00 | 1.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,364.17 | 67 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Sunosi Normalized: sunosi |
Drug | Axsome Therapeutics, Inc. | $181.07 | 9 | 2025 |
Source payment records
|
|||||
| Prolastin-C Liquid Normalized: prolastin c liquid |
Biological | Grifols USA, LLC | $159.34 | 6 | 2025 |
Source payment records
|
|||||
| TEZSPIRE Normalized: tezspire |
Biological | Amgen Inc. | $147.96 | 12 | 2025 |
Source payment records
|
|||||
| LUMRYZ Normalized: lumryz |
Drug | Avadel CNS Pharmaceuticals, LLC | $139.56 | 7 | 2025 |
Source payment records
|
|||||
| Arikayce Normalized: arikayce |
Drug | Insmed, Inc. | $113.59 | 4 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $85.45 | 4 | 2025 |
Source payment records
|
|||||
| QUTENZA Normalized: qutenza |
Drug | Averitas Pharma Inc. | $68.82 | 1 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | GENZYME CORPORATION | $68.75 | 4 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $63.21 | 4 | 2025 |
Source payment records
|
|||||
| NUCALA Normalized: nucala |
Biological | GlaxoSmithKline, LLC. | $58.24 | 3 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $52.47 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $41.04 | 2 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $36.13 | 2 | 2025 |
Source payment records
|
|||||
| GLASSIA Normalized: glassia |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $34.20 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $33.00 | 1 | 2025 |
Source payment records
|
|||||
| Xembify Normalized: xembify |
Biological | Grifols USA, LLC | $30.91 | 1 | 2025 |
Source payment records
|
|||||
| Brinsupri Normalized: brinsupri |
Drug | Insmed, Inc. | $19.02 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $17.41 | 1 | 2025 |
Source payment records
|
|||||
| ACTHAR Normalized: acthar |
Biological | Mallinckrodt Hospital Products Inc. | $17.02 | 1 | 2025 |
Source payment records
|
|||||
| JASCAYD Normalized: jascayd |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $16.00 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AIRSUPRA airsupra |
2025 | Airsupra | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Sunosi sunosi |
2025 | Sunosi | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 609 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | AIRSUPRA open payments reported associated product |
CMS Open Payments — General Payments 165148 supporting records · 56069 recipient NPIs · example record 1206131344 |
Airsupra · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
73 | 17 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
85 | 27 |
| Axsome Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | Sunosi open payments reported associated product |
CMS Open Payments — General Payments 19758 supporting records · 6305 recipient NPIs · example record 1235293059 |
Sunosi · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | OFEV open payments reported associated product |
CMS Open Payments — General Payments 14236 supporting records · 6873 recipient NPIs · example record 1221811762 |
Ofev · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
609 | 152 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Albuterol Sulfate Hfa | Albuterol Sulfate | 629 | 212 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 609 | 152 |
| Amlodipine Besylate | Amlodipine Besylate | 300 | 89 |
| Prednisone | Prednisone | 266 | 111 |
| Methylprednisolone | Methylprednisolone | 255 | 167 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 247 | 79 |
| Montelukast Sodium | Montelukast Sodium | 244 | 77 |
| Atorvastatin Calcium | Atorvastatin Calcium | 234 | 77 |
| Losartan Potassium | Losartan Potassium | 214 | 66 |
| Duloxetine Hcl | Duloxetine Hcl | 202 | 48 |
| Gabapentin | Gabapentin | 202 | 58 |
| Omeprazole | Omeprazole | 180 | 52 |
| Azithromycin | Azithromycin | 171 | 98 |
| Metoprolol Succinate | Metoprolol Succinate | 171 | 48 |
| Furosemide | Furosemide | 156 | 49 |
| Fluticasone Propionate | Fluticasone Propionate | 153 | 65 |
| Trazodone Hcl | Trazodone Hcl | 143 | 34 |
| Simvastatin | Simvastatin | 140 | 34 |
| Famotidine | Famotidine | 131 | 42 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 131 | 39 |
| Metformin Hcl | Metformin Hcl | 124 | 38 |
| Levothyroxine Sodium | Levothyroxine Sodium | 119 | 38 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 117 | 35 |
| Lisinopril | Lisinopril | 115 | 36 |
| Pantoprazole Sodium | Pantoprazole Sodium | 114 | 41 |
| Roflumilast | Roflumilast | 101 | 25 |
| Breo Ellipta | Fluticasone/Vilanterol | 98 | 27 |
| Meloxicam | Meloxicam | 97 | 32 |
| Eliquis | Apixaban | 96 | 33 |
| Buspirone Hcl | Buspirone Hcl | 93 | 27 |
| Pravastatin Sodium | Pravastatin Sodium | 93 | 29 |
| Potassium Chloride | Potassium Chloride | 88 | 25 |
| Spironolactone | Spironolactone | 88 | 23 |
| Symbicort | Budesonide/Formoterol Fumarate | 85 | 27 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 84 | 71 |
| Allopurinol | Allopurinol | 82 | 25 |
| Metformin Hcl Er | Metformin Hcl | 77 | 23 |
| Doxycycline Hyclate | Doxycycline Hyclate | 76 | 67 |
| Farxiga | Dapagliflozin Propanediol | 73 | 17 |
| Quetiapine Fumarate | Quetiapine Fumarate | 71 | 19 |
| Tamsulosin Hcl | Tamsulosin Hcl | 70 | 22 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 68 | 12 |
| Hydrochlorothiazide | Hydrochlorothiazide | 66 | 24 |
| Ozempic | Semaglutide | 66 | 13 |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 66 | 17 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 65 | 20 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 65 | 18 |
| Metoprolol Tartrate | Metoprolol Tartrate | 64 | 21 |
| Nifedipine Er | Nifedipine | 62 | 16 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 61 | 24 |
| Alprazolam | Alprazolam | 59 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 59 | 23 |
| Levofloxacin | Levofloxacin | 55 | 40 |
| Carvedilol | Carvedilol | 54 | 19 |
| Torsemide | Torsemide | 53 | 22 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 51 | 16 |
| Sertraline Hcl | Sertraline Hcl | 51 | 17 |
| Donepezil Hcl | Donepezil Hcl | 49 | 13 |
| Hydralazine Hcl | Hydralazine Hcl | 49 | 22 |
| Linzess | Linaclotide | 48 | 14 |
| Ipratropium Bromide | Ipratropium Bromide | 46 | 16 |
| Diclofenac Sodium | Diclofenac Sodium | 45 | 24 |
| Xarelto | Rivaroxaban | 45 | 13 |
| Baclofen | Baclofen | 43 | 14 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 43 | 15 |
| Jardiance | Empagliflozin | 43 | suppressed |
| Mounjaro | Tirzepatide | 43 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 42 | suppressed |
| Celecoxib | Celecoxib | 42 | 13 |
| Glipizide | Glipizide | 42 | 11 |
| Fluconazole | Fluconazole | 40 | 30 |
| Sucralfate | Sucralfate | 40 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 39 | suppressed |
| Lorazepam | Lorazepam | 39 | 11 |
| Ropinirole Hcl | Ropinirole Hcl | 39 | 11 |
| Acetazolamide | Acetazolamide | 37 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 37 | 18 |
| Atenolol | Atenolol | 36 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 36 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 35 | suppressed |
| Ethambutol Hcl | Ethambutol Hcl | 35 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 35 | suppressed |
| Myrbetriq | Mirabegron | 35 | 11 |
| Wakix | Pitolisant Hcl | 35 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 35 | 11 |
| Clonazepam | Clonazepam | 34 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 34 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 34 | 17 |
| Warfarin Sodium | Warfarin Sodium | 34 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 33 | 28 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 33 | 25 |
| Valsartan | Valsartan | 33 | 13 |
| Vascepa | Icosapent Ethyl | 33 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 33 | 11 |
| Nateglinide | Nateglinide | 32 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 32 | 27 |
| Fluoxetine Hcl | Fluoxetine Hcl | 31 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 30 | 12 |
| Ondansetron Odt | Ondansetron | 30 | 13 |
| Clopidogrel | Clopidogrel Bisulfate | 29 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 29 | suppressed |
| Entresto | Sacubitril/Valsartan | 28 | suppressed |
| Trulicity | Dulaglutide | 28 | suppressed |
| Chlorthalidone | Chlorthalidone | 27 | suppressed |
| Clonidine | Clonidine | 27 | suppressed |
| Glimepiride | Glimepiride | 27 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Mirtazapine | Mirtazapine | 27 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 27 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 26 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 26 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 26 | suppressed |
| Nystatin | Nystatin | 25 | 20 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 24 | 11 |
| Glipizide Er | Glipizide | 24 | suppressed |
| Januvia | Sitagliptin Phosphate | 24 | suppressed |
| Lidocaine | Lidocaine | 24 | 13 |
| Tizanidine Hcl | Tizanidine Hcl | 24 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 24 | 11 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 23 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 22 | suppressed |
| Bupropion Xl | Bupropion Hcl | 22 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 22 | suppressed |
| Mupirocin | Mupirocin | 22 | 16 |
| Spiriva Respimat | Tiotropium Bromide | 22 | suppressed |
| Sunosi | Solriamfetol Hcl | 22 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 22 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 22 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 21 | suppressed |
| Memantine Hcl | Memantine Hcl | 21 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 20 | suppressed |
| Methimazole | Methimazole | 20 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 20 | suppressed |
| Ezetimibe | Ezetimibe | 19 | suppressed |
| Irbesartan | Irbesartan | 19 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 19 | suppressed |
| Topiramate | Topiramate | 19 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 18 | suppressed |
| Colchicine | Colchicine | 18 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 18 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 18 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 18 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 16 | 16 |
| Rybelsus | Semaglutide | 16 | suppressed |
| Verapamil Er | Verapamil Hcl | 16 | suppressed |
| Pregabalin | Pregabalin | 15 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 15 | suppressed |
| Aralast Np | Alpha-1-Proteinase Inhibitor | 14 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 14 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 14 | suppressed |
| Fluticasone-Vilanterol | Fluticasone/Vilanterol | 14 | suppressed |
| Novolog Flexpen | Insulin Aspart | 14 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 14 | suppressed |
| Rifampin | Rifampin | 14 | suppressed |
| Tiotropium Bromide | Tiotropium Bromide | 14 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 14 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 13 | suppressed |
| Fenofibrate | Fenofibrate | 13 | suppressed |
| Ibuprofen | Ibuprofen | 13 | suppressed |
| Ofev | Nintedanib Esylate | 13 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 12 | suppressed |
| Armodafinil | Armodafinil | 12 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 12 | suppressed |
| Dulera | Mometasone/Formoterol | 12 | suppressed |
| Latanoprost | Latanoprost | 12 | suppressed |
| Modafinil | Modafinil | 12 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 12 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 12 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Airsupra | Albuterol Sulfate/Budesonide | 11 | suppressed |
| Belsomra | Suvorexant | 11 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 11 | suppressed |
| Cephalexin | Cephalexin | 11 | 11 |
| Lansoprazole | Lansoprazole | 11 | suppressed |
| Novolog Mix 70-30 | Insulin Aspart Prot/Insuln Asp | 11 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 11 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 11 | suppressed |
| Ursodiol | Ursodiol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,364.17 · 67 records | Grifols USA, LLC | ACTHAR, AIRSUPRA, Arikayce, BREZTRI, Brinsupri, DUPIXENT, GLASSIA, JASCAYD, LUMRYZ, NUCALA, Ohtuvayre, PURIFIED CORTROPHIN GEL, Prolastin-C Liquid, QUTENZA, Sunosi, TEZSPIRE, TRELEGY ELLIPTA, Xembify, YUPELRI, ZEPBOUND | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Airsupra play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error